Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,901–4,000 of 10,906
Halder, U. C. (2021) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-021-00149-2 · Cited by 16
An Overview on the Potential Roles of EGCG in the Treatment of COVID-19 Infection
Bimonte, S., Forte, C. A., Cuomo, M., Esposito, G., Cascella, M., & Cuomo, A. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s314666 · Cited by 16
COVID-19 vaccines: A race against time
Peiffer‐Smadja, N., Rozencwajg, S., Kherabi, Y., Yazdanpanah, Y., & Montravers, P. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100848 · Cited by 16
Nonviral targeted mRNA delivery: principles, progresses, and challenges
He, X., Li, G., Huang, L., Shi, H., Zhong, S., Zhao, S., Jiao, X., Xin, J., Yin, X., Liu, S., et al. (2025) · MedComm · doi:10.1002/mco2.70035 · Cited by 28
Cozzolino, A., Hasenmajer, V., Newell-Price, J. D. C., & Isidori, A. M. (2023) · Endocrine · doi:10.1007/s12020-023-03411-w · Cited by 19
Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest
Moss, P. A. H., Berenbaum, F., Curigliano, G., Grupper, A., Berg, T., & Pather, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.067 · Cited by 18
Haq, H. N., Khan, H., Chaudhry, H., Nimmala, S., Demidovich, J., Papudesi, B. N., & Potluri, S. D. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.08.003 · Cited by 22
Law, M. F., Ho, R., Law, K. W. T., & Cheung, C. K. M. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1850 · Cited by 24
Casado, J. L., Vizcarra, P., Häemmerle, J., Velasco, H., Martín-Hondarza, A., Rodríguez-Domínguez, M., Velasco, T., Martín, S., Romero‐Hernández, B., Fernández-Escribano, M., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100165 · Cited by 17
Ledda, C., Costantino, C., Motta, G., Cunsolo, R., Stracquadanio, P., Liberti, G., Maltezou, H., & Rapisarda, V. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7010009 · Cited by 22
Golombek, S., Doll, I., Kaufmann, L., Lescan, M., Schlensak, C., & Avci‐Adali, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126599 · Cited by 16
Digital Nanomedicine: A New Frontier for Drug Development
Ho, D. (2022) · ACS Nano · doi:10.1021/acsnano.2c01835 · Cited by 18
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
Walmsley, S. L., Nabipoor, M., Lovblom, L. E., Ravindran, R., Colwill, K., McGeer, A., Dayam, R. M., Manase, D., Gingras, A., & on behalf of the STOPCoV Team (2023) · Vaccines · doi:10.3390/vaccines12010036 · Cited by 15
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 15
Lv, J., Fan, Q., Zhang, Y., Zhou, X., Yu, P., Yu, X., Xin, C., Hong, J., & Cheng, Y. (2025) · Advanced Science · doi:10.1002/advs.202413006 · Cited by 20
Ma, Y., Wang, Y., Dong, C., Gonzalez, G. X., Zhu, W., Kim, J., Wei, L., Kang, S., & Wang, B. (2022) · Small · doi:10.1002/smll.202200836 · Cited by 14
Nooraie, R. Y., Lyons, P. G., Baumann, A. A., & Saboury, B. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.07.002 · Cited by 19
Accelerating clinical trial development in vaccinology: COVID-19 and beyond
Corey, L., & Miner, M. D. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102206 · Cited by 18
Self-citationImmunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans
Goyal, K., Goel, H., Baranwal, P., Tewary, A., Dixit, A., Pandey, A. K., Benjamin, M., Tanwar, P., Dey, A., Khan, F., et al. (2021) · Immuno · doi:10.3390/immuno1040032 · Cited by 18
Fahrner, J., Lahmar, I., Goubet, A., Haddad, Y., Carrier, A., Mazzenga, M., Drubay, D., Silva, C. A. C., Lyon COVID Study Group, de Sousa, E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1441 · Cited by 22
Kapnick, S. M. (2022) · DNA and Cell Biology · doi:10.1089/dna.2021.0538 · Cited by 19
BEREZNE, A., Bougon, D., Blanc‐Jouvan, F., Gendron, N., Janssen, C., Müller, M., Bertil, S., Desvard, F., Présot, I., Terrier, B., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12572 · Cited by 16
Chiampas, G., & Ibiebele, A. L. (2021) · Sports Medicine · doi:10.1007/s40279-021-01503-z · Cited by 17
Xu, Y., Li, H., Kirui, B. K., Santosa, A., Gisslén, M., Leach, S., Wettermark, B., Vanfleteren, L. E. G. W., & Nyberg, F. (2022) · Vaccines · doi:10.3390/vaccines10122074 · Cited by 19
Peralta-Amaro, A. L., Tejada-Ruíz, M. I., Rivera-Alvarado, K. L., Cobos-Quevedo, O., Romero-Hernández, P., Macías-Arroyo, W., Avendaño-Ponce, A., Hurtado-Díaz, J., Lastra, O. L. V., & Hernández, A. L. (2022) · Vaccines · doi:10.3390/vaccines10010126 · Cited by 16
Eick-Cost, A. A., Ying, S., & Wells, N. Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8071 · Cited by 18
Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines
Cen, J., Hou, M., & Liu, S. (2023) · Giant · doi:10.1016/j.giant.2023.100169 · Cited by 18
Alshehri, S., & Sallam, M. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2275962 · Cited by 18
Association between COVID-19 vaccination and menstruation: a state of the science review
Payne, L. A., Wise, L. A., Wesselink, A. K., Wang, S., Missmer, S. A., & Edelman, A. B. (2024) · BMJ Sexual & Reproductive Health · doi:10.1136/bmjsrh-2024-202274 · Cited by 19
Pettigrew, Z. J., Kim, M. H., & Becker‐Dreps, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_12 · Cited by 18
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
Markewitz, R. D. H., Juhl, D., Pauli, D., Görg, S., Junker, R., Rupp, J., Engel, S., Steinhagen, K., Herbst, V., Zapf, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811020 · Cited by 14
Feitsma, E., Janssen, Y., Boersma, H., van Sleen, Y., van Baarle, D., Alleva, D., Lancaster, T. M., Sathiyaseelan, T., Murikipudi, S., Delpero, A., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.057 · Cited by 15
Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study
Stivanello, E., Beghelli, C., Cardoni, F., Giansante, C., Marzaroli, P., Musti, M. A., Perlangeli, V., Todeschini, R., & Pandolfi, P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.039 · Cited by 14
Association of Zip Code Vaccination Rate With COVID-19 Mortality in Chicago, Illinois
Zeng, S., Pelzer, K. M., Gibbons, R. D., Peek, M. E., & Parker, W. F. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.14753 · Cited by 19
Kwok, W. C., Tam, A. R., Ho, J., Lam, D. C. L., Tam, T. C. C., Chan, K. F., Wang, J. K. L., Ip, M., & Hung, I. F. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13480 · Cited by 15
Kayabölen, A., Akcan, U., Özturan, D., Polat, H. Ü., Şahin, G. N., Degirmenci, N. P., Bayraktar-Odabas, C., Söyler, G., Sarayloo, E., Nurtop, E., et al. (2022) · Advanced Science · doi:10.1002/advs.202201294 · Cited by 18
Malli, F., Lampropoulos, I. C., Papagiannis, D., Papathanasiou, I. V., Daniil, Z. D., & Gourgoulianis, K. I. (2022) · Vaccines · doi:10.3390/vaccines10020337 · Cited by 19
Revolutionizing mRNA Vaccines Through Innovative Formulation and Delivery Strategies
Fatima, M., An, T., & Hong, K. (2025) · Biomolecules · doi:10.3390/biom15030359 · Cited by 22
“Interest in nanocarrier-assisted mRNA delivery was sparked by the successful execution of COVID-19 mRNA vaccines (Moderna’s mRNA-1273 and Pfizer/BioNTech’s BNT162b2) [23–26].”
Advancement in the development of mRNA ‐based vaccines for respiratory viruses
Troncoso‐Bravo, T., Ramírez, M. A., Loaiza, R. A., Román-Cárdenas, C., Papazisis, G., Garrido, D. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2024) · Immunology · doi:10.1111/imm.13844 · Cited by 25
Singh, G., Abbad, A., Kleiner, G., Srivastava, K., Gleason, C., PARIS Study Group, Carreño, J. M., Simon, V. R., Krammer, F., Andre, D., et al. (2023) · mBio · doi:10.1128/mbio.02250-23 · Cited by 19
Williams, L. R., Ferguson, N. M., Donnelly, C. A., & Grassly, N. C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab914 · Cited by 15
Fava, V. M., Bourgey, M., Nawarathna, P. M., Orlova, M., Cassart, P., Vinh, D. C., Cheng, M. P., Bourque, G., Schurr, E., & Langlais, D. (2022) · Science Advances · doi:10.1126/sciadv.abm2510 · Cited by 17
Hartig, M., Stephens, C., Foster, A., Fontes, D. H., Kinzel, M., & García-Godoy, F. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211034164 · Cited by 19
Cheng, Q., Farbiak, L., Vaidya, A., Guerrero, E. D., Lee, E. E., Rose, E. K., Wang, X., Robinson, J. J., Lee, S. M., Wei, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313009120 · Cited by 20
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 18
Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women
Blix, K., Laake, I., Juvet, L. K., Robertson, A. H., Caspersen, I. H., Mjaaland, S., Skodvin, S. N., Magnus, P. M., Feiring, B., & Trogstad, L. (2023) · Science Advances · doi:10.1126/sciadv.adg1391 · Cited by 21
Magri, C., Marchina, E., Sansone, E., D’Adamo, P., Cappellani, S., Bonfanti, C., Terlenghi, L., Biasiotto, G., Zanella, I., Sala, E., et al. (2023) · HLA · doi:10.1111/tan.15157 · Cited by 21
Avcı, H., Karabulut, B., Eken, H. D., Faraşoğlu, A., Çakıl, T., Çoruk, S., Özel, H., Kaya, N. K., & Özbalta, S. Ö. (2021) · Ear Nose & Throat Journal · doi:10.1177/01455613211028493 · Cited by 18
Selma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2021) · medRxiv · doi:10.1101/2021.05.20.21257512 · Cited by 16
Spiteri, G., D’Agostini, M., Abedini, M., Ditano, G., Collatuzzo, G., Boffetta, P., Vimercati, L., Sansone, E., Palma, G. D., Modenese, A., et al. (2024) · Infection · doi:10.1007/s15010-024-02189-x · Cited by 15
Su, E., Fischer, S., Steingruber, R. D., Nigg, S., Güsewell, S., Albrich, W. C., Rothermundt, C. A., Silzle, T., & Kahlert, C. R. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100587 · Cited by 15
Mayer-Blackwell, K., Ryu, H., Codd, A. S., Parks, K. R., MacMillan, H. R., Cohen, K. W., Stewart, T. L., Seese, A. M., Lemos, M. P., Rosa, S. C. D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101149 · Cited by 21
Dalvie, N. C., Rodriguez‐Aponte, S. A., Hartwell, B. L., Tostanoski, L. H., Biedermann, A. M., Crowell, L. E., Kaur, K., Kumru, O. S., Carter, L. P., Yu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433558 · Cited by 18
Dicembrini, I., Vitale, V., Cosentino, C., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01837-0 · Cited by 16
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy
Iovino, L., Thur, L. A., Gnjatic, S., Chapuis, A. G., Milano, F., & Hill, J. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002392 · Cited by 19
Kamura, Y., Terao, T., Akao, S., Kono, Y., Honma, K., & Matsue, K. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.031 · Cited by 17
Williams, N., Rosenblum, M., & Diaz, I. M. (2022) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/rssa.12915 · Cited by 23
Bell's palsy following COVID-19 vaccine administration in HIV+ patient
Mussatto, C. C., Sokol, J. A., & Alapati, N. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101259 · Cited by 15
mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13974 · Cited by 16
Case report of acute encephalitis following the AstraZeneca COVID‐19 vaccine
Li, S., Chen, H., Liu, P., Shi, Z., Lin, Y., Tsai, C.-A., & Lin, S. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14372 · Cited by 15
Mostafa, H. H., Luo, C. H., Morris, C. P., Li, M., Swanson, N. J., Amadi, A., Gallagher, N., & Pekosz, A. S. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105151 · Cited by 18
Effective transcatheter intracoronary delivery of mRNA-lipid nanoparticles targeting the heart
Handa, K., Kawamura, M., Sasai, M., Matsuzaki, T., Harada, A., Fujimura, L., Whitehouse, J., Saito, S., Komukai, S., Kitamura, T., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113623 · Cited by 22
Fopase, R., Panda, C., Rajendran, A. P., Uludağ, H., & Pandey, L. M. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1112755 · Cited by 18
Wang, C., Chen, C., Lu, C., Chen, W., Hui, R. C., Chiu, T., Chi, M., Lin, J.-C., Huang, Y., Chang, Y., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103054 · Cited by 17
Italian association for the study of the liver position statement on SARS-CoV2 vaccination
Russo, F. P., Piano, S. S., Bruno, R., Burra, P., Puoti, M., Masarone, M., Montagnese, S., Ponziani, F. R., Petta, S., & Aghemo, A. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.03.013 · Cited by 18
Deep venous thrombosis and pulmonary embolism after COVID-19 mRNA vaccination
Atoui, A., Jarrah, K., Mahmasani, L. A., Bou‐Fakhredin, R., & Taher, A. T. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04743-1 · Cited by 18
Reimagining drug nanocarriers: clinical realities and smarter strategies for targeted drug delivery
Baker, A. G., & Fruk, L. (2025) · Materials Horizons · doi:10.1039/d5mh00927h · Cited by 21
Comprehensive antibody profiling of mRNA vaccination in childrenPreprint
Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.07.463592 · Cited by 16
Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Silvestri, M. A., Berrios, J. R. G., Virtuoso, A., Marrucci, E., Signorelli, C., Chilelli, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.009 · Cited by 15
Flynn, J. A., Weber, T., Cejas, P. J., Cox, K. S., Touch, S., Austin, L. A., Ou, Y., Citron, M. P., Luo, B., Gindy, M. E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.063 · Cited by 16
SARS-CoV-2 inflammation durably imprints memory CD4 T cells
Gray-Gaillard, S. L., Solis, S., Chen, H. M., Monteiro, C., Ciabattoni, G. O., Samanovic, M. I., Cornelius, A. R., Williams, T., Geesey, E., Rodriguez, M., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adj8526 · Cited by 28
Kim, J. S., Sun, Y., Balte, P., Cushman, M., Boyle, R., Tracy, R. P., Styer, L. M., Bell, T. D., Anderson, M. R., Allen, N. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45468-9 · Cited by 24
Sankhala, R. S., Lal, K. G., Jensen, J. L., Dussupt, V., Mendez-Rivera, L., Bai, H., Wieczorek, L., Mayer, S. V., Zemil, M., Wagner, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44265-0 · Cited by 15
Critical Challenges and Future Direction in Extracellular Vesicle Research and Commercialization
Park, S. J., & Jung, H. (2025) · BioChip Journal · doi:10.1007/s13206-025-00232-z · Cited by 23
“LNP technology in particular has rev-olutionized nucleic acid delivery, enabling the first FDA-approved siRNA drug (patisiran) [81] and the rapid deployment of COVID-19 mRNA vaccines [78] on a global scale.”
Verleye, A., Wijtvliet, V. P. W. M., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., Ariën, K. K., Winter, B. Y. D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac174 · Cited by 17
Drzeniek, N. M., Kahwaji, N., Schlickeiser, S., Reinke, P., Geißler, S., Volk, H., & Gossen, M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121971 · Cited by 17
Yakoubi, A., & Dhafer, C. E. B. (2022) · Plasmonics · doi:10.1007/s11468-022-01754-0 · Cited by 16
Davenport, B., Morrison, T. E., Kedl, R. M., & Klarquist, J. S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100195 · Cited by 16
Delivery of mRNA Using Biomimetic Vectors: Progress and Challenges
Yin, M., Sun, H., Li, Y., Zhang, J., Wang, J., Liang, Y., & Zhang, K. (2024) · Small · doi:10.1002/smll.202402715 · Cited by 19
Raddad, L. J. A., Chemaitelly, H., Ayoub, H., Yassine, H., Benslimane, F., Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., Al-Kanaani, Z., et al. (2021) · medRxiv · doi:10.1101/2021.07.25.21261093 · Cited by 15
Rouger, J., Bertrand, Y., Boissel, N., Brethon, B., Ducassou, S., Gandemer, V., Domenech, C., Leblanc, T. M., Leverger, G., Michel, G., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.004 · Cited by 16
A cohort of mRNAs undergo high-stoichiometry NSUN6-mediated site-specific m5C modification
Zhang, Y., Li, C., Zhou, Y.-J., Li, H., Li, J., Xiong, Q.-P., Zhou, W., Huang, W., Zhang, Q. C., Xiang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60873-4 · Cited by 20
Accelerating discoveries in cancer nanomedicine using AI
Guan, C., Mendes, B. B., Conniot, J., Dias, A. L., Hammad, L., Thambi, T., Langer, R., Rodrigues, T., Conde, J., & de la Fuente‐Núñez, C. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100279 · Cited by 20
Dolzhikova, I. V., Gushchin, V. А., Shcheblyakov, D. V., Tsybin, A. N., Shchetinin, A. M., Pochtovyi, A. A., Komissarov, A. B., Kleymenov, D. A., Kuznetsova, N. A., Ильдарович, Т. А., et al. (2021) · medRxiv · doi:10.1101/2021.10.08.21264715 · Cited by 18
Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challengePreprint
Hou, F., Zhang, Y., Liu, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.19.517190 · Cited by 16
Rosenecker, J., Guan, S., Darmstädter, M., & Xu, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081281 · Cited by 17
Leclerc, M., Redjoul, R., Bouter, A. L., Beckerich, F., Robin, C., Parinet, V., Pautas, C., Menouche, D., Bouledroua, S., Roy, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01250-2 · Cited by 16
Sun, X., Zhao, X., Xu, Y., Yan, Y., Li, H., Wei, M., & He, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216794 · Cited by 20
Corona and Reproduction, or Why the Corona Vaccination Does Not Result in Infertility
Braun, A.-S., Feil, K., Reiser, E., Weiß, G., von Steuben, T., Pinggera, G., Köhn, F., & Tóth, B. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1750-9284 · Cited by 17
COVID-19 vaccination: Why extend the interval between doses?
Quach, C., & Deeks, S. L. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2021-0323 · Cited by 16
Moser, T., Otto, F., O'Sullivan, C., Hitzl, W., Pilz, G., Harrer, A., Trinka, E., & Wipfler, P. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103560 · Cited by 16
Castro‐Balado, A., Mondelo‐García, C., Barbosa‐Pereira, L., Varela-Rey, I., Novo‐Veleiro, I., Vázquez-Agra, N., López, J. R. A., Bandín‐Vilar, E., Sendón, R., Busto-Iglesias, M., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030342 · Cited by 16
Kemerley, A., Gupta, A., Thirunavukkarasu, M., Maloney, M., Burgwardt, S., & Maulik, N. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030124 · Cited by 20
Vahidy, F., Pischel, L., Tano, M., Pan, A. P., Boom, M. L., Sostman, H. D., Nasir, K., & Omer, S. B. (2021) · medRxiv · doi:10.1101/2021.04.21.21255873 · Cited by 18
RetractedRomero-Ibarguengoitia, M. E., González‐Cantú, A., Pozzi, C., Levi, R., Mollura, M., Sarti, R., Sanz‐Sánchez, M. Á., Rivera-Salinas, D., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894277 · Cited by 20
Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation
Atsavapranee, E., Haley, R. M., Billingsley, M. M., Chan, A., Ruan, B., Figueroa‐Espada, C. G., Gong, N., Mukalel, A. J., Bryan, P. N., & Mitchell, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.015 · Cited by 16
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.